Ocular Therapeutix™ Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
Anticipating DEXTENZA™ NDA Resubmission in the First Half of 2018
“It gives me great pleasure to turn the page on 2017 and look forward to
2018 with a rebuilt team in place and an exciting set of near-term
opportunities before us,” said
Key Highlights and Upcoming Events
DEXTENZA™ New Drug Application (NDA) resubmission to the
U.S. Food and Drug Administration( FDA) remains on track for the first half of 2018. DEXTENZA is a long-acting form of dexamethasone that uses Ocular Therapeutix’s proprietary hydrogel technology to treat post-surgical ocular pain and inflammation. In November, the Company completed its formal response to the May 2017FDA Form 483 in which the Company addressed the FDA’s observations concerning the manufacturing processes of and analytical testing related to DEXTENZA. In December the Company requested a meeting with the FDAto describe its remediation efforts and resubmission plans and seek feedback. A meeting was granted in January and preliminary written responses from the FDAto the Company’s questions fully addressed its meeting objectives. The Company determined that the meeting would no longer be necessary because of the completeness of the FDA’s response and that the FDA’s comments have not required any substantial change in its manufacturing or regulatory plans. Subject to satisfactorily addressing the FDAinspectional observations and demonstrating consistency in its commercial stage manufacturing process, the Company plans to resubmit its NDA for DEXTENZA for the treatment of post-surgical pain in the first half of 2018 and would then expect a decision from the FDAby the end of 2018.
Topline efficacy data from the Phase 3 Trial of OTX-TP
(travoprost insert) for mild to moderate glaucoma expected in second
half 2018. In 2016, the Company began enrollment of its first
Phase 3 clinical trial, a 550-patient prospective, multi-center,
randomized, parallel-arm, double masked, vehicle-controlled trial to
evaluate the safety and efficacy of OTX-TP in the treatment of
subjects with open-angle glaucoma or ocular hypertension. The primary
efficacy endpoint is the statistically superior reduction of
intraocular pressure (IOP) from baseline with OTX-TP compared to
placebo inserts at 2, 6 and 12 weeks following insertion. These
include statistically superior IOP reduction at three diurnal time
8:00 AM, 10:00 AM, and 4:00 PM, at each of these weeks. In addition, while not a primary endpoint, the IOP reduction will also need to be clinically meaningful for regulatory approval. The Company expects to have topline efficacy results in the fourth quarter of 2018.
Submitted U.S. Investigational New Drug (IND) Application for
OTX-TIC (travoprost implant) and plans to initiate the U.S. Phase 1
clinical trial in the first half 2018. OTX-TIC is Ocular
Therapeutix’s second glaucoma program and it targets a more severe
patient population. The Company is developing OTX-TIC as its
bioresorbable travoprost-containing hydrogel implant delivered via an
intracameral injection. OTX-TIC targets patients with moderate to
severe glaucoma who need a higher level of intraocular pressure
reduction. The Company has initiated a Phase 1 clinical trial with
the United States. This trial is a prospective, single-center study designed to evaluate the safety, efficacy and tolerability of OTX-TIC compared to travoprost eye drops in patients with primary open-angle glaucoma or ocular hypertension. The Company also submitted a U.S. IND in the first quarter of 2018 enabling it to conduct a multi-center, open label, clinical trial evaluating the safety, efficacy, durability, and tolerability of OTX-TIC in patients in the same indication. Based on the results from these trials, the Company plans to advance OTX-TIC into a full development program.
- Expect to initiate ex-U.S. Phase 1 clinical trial for OTX-TKI (Tyrosine Kinase Inhibitor Implant) in the first half of 2018. OTX-TKI is a bioresorbable, hydrogel fiber implant with anti-angiogenic properties, delivered by intravitreal injection. Preclinical data have demonstrated the ability to deliver an efficacious dose of TKI to the posterior segment of the eye for the treatment of VEGF-induced retinal leakage for an extended duration of up to twelve months. The Company is currently planning for a Phase 1 clinical trial to begin outside the U.S. in the first half of 2018. The trial will be a multi-center, open label, dose escalation study to test the safety, durability, and tolerability of OTX-TKI. The Company also plans to evaluate biological activity by following visual acuity over time and measuring retinal thickness using standard optical coherence tomography (OCT).
- Continuing progress with Regeneron for the development of a sustained release formulation of VEGF trap aflibercept. Regeneron initiated a non-human primate trial of an extended release hydrogel-based formulation of its protein-based anti-vascular endothelial growth factor (VEGF) trap, aflibercept, for the treatment of wet age-related macular degeneration (wet AMD) in early 2018. The Company remains encouraged about the engagement of both teams and the multiple possibilities this partnership could lead to.
Completed the transition of the management team.
Ocular Therapeutixexpanded its leadership team with the additions of Naymisha Patel, Vice President of Quality and Kevin Hanley, Senior Vice President, Technical Operations. Naymisha brings over 20 years of experience working with blue-chip biotechnology companies and she has a proven record in quality management, process improvement, regulatory submissions and regulatory compliance. Kevin joins the Company from Pfizer and brings to the Company over 30 years of experience managing biopharmaceutical technical operations, with demonstrated success in technology transfer and process scale-up for the manufacturing of proteins from development through manufacturing approval. These appointments to the management team represent critical additions to ensure the Company’s core DEXTENZA manufacturing capabilities meet cGMP standards and that the Company can supply the anticipated commercial needs of DEXTENZA ahead of a potential FDAapproval. Since July 2017 Ocular Therapeutixhas appointed new team members to six of the top nine management positions in the Company, bringing in over 100 years of biopharmaceutical experience.
Fourth Quarter and Year End 2017 Financial Results
January 2018, Ocular Therapeutixcompleted a follow-on public offering raising net proceeds of $35.1 millionthat consisted of 7,475,000 shares of common stock, including those shares exercised by the underwriter of its option to purchase additional shares, pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission.
- As of December 31, 2017, cash, cash equivalents and marketable securities totaled $41.5 million. Cash used in operating activities was $10.4 million in the fourth quarter of 2017 and $50.5 million for the year ended December 31, 2017.
There was $18.0 million in outstanding debt as of December 31, 2017
with an interest-only payment period through
February 1, 2018.
- Ocular Therapeutix reported a net loss of approximately $(13.1) million, or $(0.44) per share, for the quarter ended December 31, 2017, compared to a net loss of $(12.8) million, or $(0.52) per share, for the quarter ended December 31, 2016. The fourth quarter 2017 results include $2.6 million in non-cash charges for stock-based compensation and depreciation compared to $2.0 million in such non-cash charges in the fourth quarter of 2016. The Company reported a net loss of approximately $(63.4) million, or $(2.20) per share, for the year ended December 31, 2017, compared to a net loss of $(44.7) million, or $(1.80) per share, for the year ended December 31, 2016. The 2017 results include $8.9 million in non-cash charges for stock-based compensation and depreciation compared to $6.8 million in such non-cash charges in 2016.
- Total costs and operating expenses for the three and twelve month periods ended December 31, 2017 were $13.2 million and $63.8 million, respectively, as compared to $12.9 million and $45.2 million for the comparable periods in 2016. Research and development (R&D) expenses for the three and twelve month periods ended December 31, 2017 were $7.9 million and $30.9 million, respectively, compared to $7.3 million and $27.1 million for the comparable periods in 2016. The Company continues to advance the clinical and preclinical development of its hydrogel platform technology and its portfolio of drug product candidates.
- Ocular Therapeutix generated $0.5 million and $1.9 million in revenue during the three month and twelve month periods ended December 31, 2017 from product sales of ReSure® Sealant and from collaborations with corporate partners.
- As of December 31, 2017, there were approximately 29.7 million shares issued and outstanding.
Based on the proceeds from the January offering plus existing cash
on-hand, the Company believes that it has adequate cash to fund its
operating expenses, debt service obligations and capital expenditures
requirements through the first quarter of 2019. This forecast does not
include a potential
$10 millionoption payment under the Regeneron collaboration that would be due if Regeneron determines to advance the program into human clinical trials.
Conference Call & Webcast Information
Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 8:30 am Eastern Time to discuss the Company's financial results and provide a general business update.
The live webcast can be accessed by visiting the investor section of the Company’s website at investors.ocutx.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 9371369. An archive of the webcast will be available until
About Ocular Therapeutix, Inc.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including the development and regulatory status of the Company’s product candidates, such as the Company’s regulatory submissions for and the timing and conduct of, or implications of results from, clinical trials of DEXTENZA™ for the treatment of post-surgical ocular pain and inflammation, including with respect to manufacturing deficiencies identified by the
Ocular Therapeutix, Inc.
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
|Three Months Ended||Year Ended|
|December 31,||December 31,|
|Costs and operating expenses:|
|Cost of product revenue||113||127||457||443|
|Research and development||7,908||7,328||30,880||27,065|
|Selling and marketing||903||2,526||17,000||6,701|
|General and administrative||4,279||3,002||15,509||11,004|
|Total costs and operating expenses||13,203||12,983||63,846||45,213|
|Loss from operations||(12,716)||(12,472)||(61,923)||(43,326)|
|Other income (expense):|
|Other income (expense), net||−||−||5||(1)|
|Total other expense, net||(386)||(350)||(1,463)||(1,377)|
|Net loss per share, basic and diluted||$||(0.44)||$||(0.52)||$||(2.20)||$||(1.80)|
|Weighted average common shares outstanding, basic and diluted||29,658,202||24,888,602||28,818,196||24,816,348|
|Other comprehensive income (loss):|
|Unrealized gain on marketable securities||—||(10)||5||63|
|Total other comprehensive income||—||(10)||5||63|
|Total comprehensive loss||$||(13,102)||$||(12,832)||$||(63,381)||$||(44,640)|
(In thousands, except share and per share data)
|December 31,||December 31,|
|Cash and cash equivalents||$||41,538||$||32,936|
|Prepaid expenses and other current assets||1,453||1,390|
|Total current assets||43,339||69,898|
|Property and equipment, net||10,478||3,313|
|Liabilities and Stockholders’ Equity|
|Accrued expenses and deferred rent||4,310||4,635|
|Notes payable, net of discount, current||5,545||1,549|
|Total current liabilities||13,426||8,300|
|Deferred rent, long-term||3,387||537|
|Notes payable, net of discount, long-term||12,471||14,094|
|Commitments and contingencies (Note 13)|
|Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2017 and December 31, 2016; no shares issued or outstanding at December 31, 2017 and December 31, 2016||—||—|
|Common stock, $0.0001 par value; 100,000,000 shares authorized at December 31, 2017 and December 31, 2016; 29,658,202 and 25,024,100 shares issued and outstanding at December 31 2017 and December 31, 2016, respectively||3||3|
|Additional paid-in capital||263,409||225,889|
|Accumulated other comprehensive loss||—||(5)|
|Total stockholders’ equity||26,147||52,008|
|Total liabilities and stockholders’ equity||$||55,431||$||74,939|
Chief Financial Officer
Vice President of Marketing & Commercial Operations